Tozinameran

托兹奈米瑞

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTozinameran
Drug Alias NamePfizer-BioNTech COVID-19 vaccine新型冠状病毒mRNA疫苗（Biontech）BNT162b2 vaccinePfizer COVID-19 VaccinePfizer-BioNTech COVID-19 bivalent mRNA vaccine +[18] 
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsAnaphylaxis +[13] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2020/12/02
Country/TerritoryCanadaUnited StatesPoland +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBiontech SePfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdInstitut National De La Santé Et De La Recherche Médicale, France U979Eurofarma +[15] 
Inactive CompaniesPharmajet IncThe University Of Hong KongDHR Health Institute For Research & Development +[4] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsAnaphylaxis +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeJ07BX
Related LinksWikipediaDrugBankKEGG